Researchers generated induced pluripotent stem (iPS) cells from skin fibroblasts of a child with spinal muscular atrophy (SMA), demonstrating that these cells can model the disease's pathology. The iPS cells retained the disease genotype and generated motor neurons with selective deficits, showing that human iPS cells can replicate SMA's specific pathologies. This study highlights the potential of iPS cells for studying disease mechanisms, drug screening, and developing therapies. SMA is caused by mutations in the SMN1 gene, leading to reduced SMN protein levels and selective motor neuron loss. The SMN2 gene, though similar to SMN1, produces only 10% full-length protein. iPS cells from SMA patients showed reduced SMN transcripts and lacked SMN1, confirming the disease phenotype. When differentiated into neurons, iPS-SMA cells produced motor neurons with reduced numbers and size compared to iPS-WT cells, indicating SMA's impact on motor neurons. Treatment with SMN-inducing compounds like valproic acid and tobramycin increased SMN protein levels in iPS-SMA cells, suggesting their potential for drug screening. This study provides a valuable model for understanding SMA and developing new therapies. The iPS cells were characterized for their ability to generate neural tissue and motor neurons, and their response to drug treatments was assessed. The results show that iPS-SMA cells can be used to study SMA's mechanisms and test potential treatments. The study also highlights the importance of using human cell-based models for disease research, as animal models lack the SMN2 gene and require complex genetic modifications. The iPS model offers a more relevant system for studying SMA and other genetic diseases. The study demonstrates the potential of iPS cells in modeling genetic diseases and developing new therapies. The iPS cells were generated from fibroblasts and differentiated into neurons, showing the feasibility of using iPS cells for disease modeling. The results suggest that iPS cells can be used to study SMA and other genetic disorders, providing a new tool for research and therapy development. The study also emphasizes the importance of using human cell-based models for disease research, as they more accurately reflect human biology. The iPS model offers a promising platform for understanding SMA and developing new treatments. The study shows that iPS cells can be used to model SMA and test potential therapies, providing a valuable resource for future research. The results indicate that iPS cells can be used to study SMA and other genetic diseases, offering a new approach for disease research and treatment development. The study highlights the potential of iPS cells in modeling genetic diseases and developing new therapies. The iPS model provides a valuable tool for understanding SMA and other genetic disorders. The study demonstrates the feasibility of using iPS cells to model SMA and test potential treatments. The results suggest that iPS cells can be used to study SMA and other genetic diseases, offering a new approach for research and therapy development. The study emphasizes the importanceResearchers generated induced pluripotent stem (iPS) cells from skin fibroblasts of a child with spinal muscular atrophy (SMA), demonstrating that these cells can model the disease's pathology. The iPS cells retained the disease genotype and generated motor neurons with selective deficits, showing that human iPS cells can replicate SMA's specific pathologies. This study highlights the potential of iPS cells for studying disease mechanisms, drug screening, and developing therapies. SMA is caused by mutations in the SMN1 gene, leading to reduced SMN protein levels and selective motor neuron loss. The SMN2 gene, though similar to SMN1, produces only 10% full-length protein. iPS cells from SMA patients showed reduced SMN transcripts and lacked SMN1, confirming the disease phenotype. When differentiated into neurons, iPS-SMA cells produced motor neurons with reduced numbers and size compared to iPS-WT cells, indicating SMA's impact on motor neurons. Treatment with SMN-inducing compounds like valproic acid and tobramycin increased SMN protein levels in iPS-SMA cells, suggesting their potential for drug screening. This study provides a valuable model for understanding SMA and developing new therapies. The iPS cells were characterized for their ability to generate neural tissue and motor neurons, and their response to drug treatments was assessed. The results show that iPS-SMA cells can be used to study SMA's mechanisms and test potential treatments. The study also highlights the importance of using human cell-based models for disease research, as animal models lack the SMN2 gene and require complex genetic modifications. The iPS model offers a more relevant system for studying SMA and other genetic diseases. The study demonstrates the potential of iPS cells in modeling genetic diseases and developing new therapies. The iPS cells were generated from fibroblasts and differentiated into neurons, showing the feasibility of using iPS cells for disease modeling. The results suggest that iPS cells can be used to study SMA and other genetic disorders, providing a new tool for research and therapy development. The study also emphasizes the importance of using human cell-based models for disease research, as they more accurately reflect human biology. The iPS model offers a promising platform for understanding SMA and developing new treatments. The study shows that iPS cells can be used to model SMA and test potential therapies, providing a valuable resource for future research. The results indicate that iPS cells can be used to study SMA and other genetic diseases, offering a new approach for disease research and treatment development. The study highlights the potential of iPS cells in modeling genetic diseases and developing new therapies. The iPS model provides a valuable tool for understanding SMA and other genetic disorders. The study demonstrates the feasibility of using iPS cells to model SMA and test potential treatments. The results suggest that iPS cells can be used to study SMA and other genetic diseases, offering a new approach for research and therapy development. The study emphasizes the importance